Has Michael Miedema, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,019 in general payments to Michael Miedema, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Miedema, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Miedema, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Miedema, MD

Cardiovascular Disease · Minneapolis, MNNPI 1922275049

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,000 of the $7,019 with a category attached, or 71.2%. Canon Medical Informatics, Inc. accounts for 71.2% of it on its own, with 3 other manufacturers making up the rest.

$7,019in general payments, 2019–2025

Across 6 payments — averaging $1169.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Canon Medical Informatics, Inc.$5K
Abbott$1K
Heartflow, Inc.$870
Regeneron Healthcare Solutions, Inc.$12

$60,504in research payments, 2019–2025

Across 18 payments — averaging $3361.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Cleerly, Inc.$60K
Amgen$978

What the payments were for

Consulting fees$2,00629%
Speaking & faculty fees$5,00071%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Canon Medical Informatics, Inc.	2	$5,000
Abbott	1	$1,136
Heartflow, Inc.	2	$870
Regeneron Healthcare Solutions, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vitrea V-Score$4,999
PROCLAIM$1,136
FFRct$870

How this compares

$7,019 in reported general payments places this provider in the 70th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$132,194

Medicare patients

975

Services billed

6,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Repatha SureclickEvolocumab	245	$293,185
EliquisApixaban	151	$185,394
XareltoRivaroxaban	45	$60,949
Praluent PenAlirocumab	56	$54,005
OzempicSemaglutide	32	$49,498
WegovySemaglutide	19	$29,231
JardianceEmpagliflozin	14	$14,689
Ezetimibe	486	$11,342
Rosuvastatin Calcium	718	$9,658
LivaloPitavastatin Calcium	11	$4,338
Metoprolol Succinate	267	$3,981
Atorvastatin Calcium	150	$1,710
Irbesartan	55	$1,277
Losartan Potassium	85	$1,216
Carvedilol	89	$1,078

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Minneapolis

Jeffrey ChambersMinneapolis$3.2M
Markus MeyerMinneapolis$786K
Robert SchwartzMinneapolis$502K
Robert VantasselMinneapolis$493K
Nedaa SkeikMinneapolis$453K
Joao CavalcanteMinneapolis$384K
Inderjit AnandMinneapolis$384K
David HurrellMinneapolis$205K
Yader Sandoval PichardoMinneapolis$157K
Charles HerzogMinneapolis$157K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →